ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2388

Women and Men with Rheumatoid Arthritis Present with Different Risks for Glucocorticoid-Related Comorbidities

Dörte Huscher1, Katinka Albrecht1, Frank Buttgereit2, Thorsten Eidner3, Stefan Kleinert4, Wolfgang Ochs5 and Angela Zink6, 1Epidemiology Unit, German Rheumatism Research Centre (DRFZ), Berlin, Germany, 2Department of Rheumatology and Clinical Immunology, Charité Univeris, Berlin, Germany, 3Rheumatology/ Osteology, Friedrich-Schiller-University Jena, University Clinic, Jena, Germany, 4Rheumatologie, Praxisgemeinschaft Rheumatologie-Nephrologie, Rheumatologische Schwerpunktpraxis, Erlangen, Germany, 5Internistisch-rheumatologische Praxisgemeinschaft Bayreuth, Bayreuth, Germany, 6Epidemiology Unit / Rheumatology and Clinical Immunology, German Rheumatism Research Centre (DRFZ) / Charité University Hospital, Berlin, Germany

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Comorbidity, rheumatoid arthritis (RA) and sex bias

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 7, 2017

Title: Rheumatoid Arthritis – Clinical Aspects Poster III: Comorbidities

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Osteoporosis, diabetes, hypertension and cardiovascular diseases are the most threatening glucocorticoid (GC)-related comorbidities in rheumatoid arthritis (RA), both from the patients and rheumatologists perspective1. The aim of the study was to evaluate gender differences in the prevalence of GC-related comorbidities in patients with RA in the National Database of the German Collaborative Arthritis Centres.

Methods: Cross-sectional data of patients with RA with valid information on body mass index (BMI) and comorbidities (n=4,438) were analysed regarding the prevalence of osteoporosis, diabetes, cardiac disease and hypertension in women and men, stratified by age, BMI, disease activity (DAS28), education, smoking and GC use (no/≤5/>5-7.5/>7.5mg  prednisone-equivalent per day). Gender differences were compared to those in the age-matched general population. Uni- and multivariable logistic regression analysis was applied to examine background risks in women and men.

Results: Data of 3,353 women and 1,085 men were available for analysis. Osteoporosis was more frequent in female (17.9% vs. 9.2%) while diabetes (10.3% vs. 15.9%), cardiac disease (9.4% vs. 18.3%) and hypertension (36.4% vs. 42.3%) were more often reported in male patients. Compared to the general population, the gender difference was 2.5 times higher for hypertension, 1.8-fold for diabetes, 1.2-fold for cardiac disease and 0.9-fold for osteoporosis. The differences persisted after stratification for GC use, disease activity, age BMI, smoking and education (Table 1). After controlling for these factors in multivariable analysis, women still had more osteoporosis (OR 2.06 [1.59-2.68]) and less diabetes (OR 0.65 [0.52-0.81]) or cardiac disease (OR 0.48 [0.38-0.61].

Conclusion: After controlling for GC use and dosage, age, lifestyle and socioeconomic factors, gender was independently associated with comorbidities that may be GC-related. We found more cardiac diseases, hypertension and diabetes in men and more osteoporosis in women. Except for osteoporosis, the gender differences for these comorbidities were higher in RA patients than in the general population.

1 Van der Goes MC, Jacobs JW, Boers M, et al. Patient and rheumatologist perspectives on glucocorticoids: an exercise to improve the implementation of the European League Against Rheumatism (EULAR) recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 2010;69:1015-21.

Table 1 Prevalence of comorbidities in female (F) and male (M) RA patients by categories of GC use, disease activity, age, BMI, smoking and educational status

 


Disclosure: D. Huscher, None; K. Albrecht, None; F. Buttgereit, None; T. Eidner, None; S. Kleinert, None; W. Ochs, None; A. Zink, AbbVie, BMS, MSD, Pfizer, Roche, UCB, 8.

To cite this abstract in AMA style:

Huscher D, Albrecht K, Buttgereit F, Eidner T, Kleinert S, Ochs W, Zink A. Women and Men with Rheumatoid Arthritis Present with Different Risks for Glucocorticoid-Related Comorbidities [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/women-and-men-with-rheumatoid-arthritis-present-with-different-risks-for-glucocorticoid-related-comorbidities/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/women-and-men-with-rheumatoid-arthritis-present-with-different-risks-for-glucocorticoid-related-comorbidities/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology